Effects of vorapaxar on QT/QTC interval in volunteers

Trial Profile

Effects of vorapaxar on QT/QTC interval in volunteers

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2012

At a glance

  • Drugs Moxifloxacin; Vorapaxar
  • Indications Acute coronary syndromes; Arterial thrombosis; Bacterial infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top